Viking Therapeutics, INC Form 4 insider transactions

Dorothy Elizabeth Kelly-Gemmell, a Director of Viking Therapeutics, Inc., reported multiple transactions in common stock on August 1, 2026.

Brian Lian, President & CEO and a Director of Viking Therapeutics, Inc., sold 148,517 shares of common stock on July 28, 2026 for $33.32 per share.

Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc., sold 21,217 shares of common stock on July 28, 2026 for $33.47 per share.

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, Inc., sold 18,217 shares of common stock on July 28, 2026 for $33.47 per share.

Viking Therapeutics Chief Medical Officer Hubert C. Chen was granted 190,000 stock options as part of an equity incentive.

Viking Therapeutics' Chief Commercial Officer, Neil William Aubuchon, was granted 180,000 stock options with an exercise price of $31.76, vesting over four years.

Viking Therapeutics' CFO, Greg Zante, reported the acquisition of substantial equity awards and subsequent tax-related share sales.

Viking Therapeutics' Chief Operating Officer, Marianna Mancini, reported the acquisition of restricted stock units and stock options, alongside sales to cover tax obligations.

Viking Therapeutics CEO Brian Lian reported the acquisition of restricted stock units and stock options, alongside sales of shares to cover tax obligations.

Viking Therapeutics Director J Matthew Singleton acquired 3,150 restricted stock units and 20,400 stock options on January 2, 2026.

Viking Therapeutics Director Lawson Macartney was granted 3,150 restricted stock units and 20,400 stock options as part of the company's 2024 Equity Incentive Plan.

Viking Therapeutics Director Charles A. Rowland Jr. received an award of 3,150 restricted stock units and 20,400 stock options.

Viking Therapeutics Director Matthew W. Foehr reported exercising stock options, selling shares, and receiving new equity awards on January 2, 2026.

Viking Therapeutics director Sarah Kathryn Rouan was granted 3,150 restricted stock units and 20,400 stock options on January 2, 2026.

Viking Therapeutics' Chief Operating Officer, Marianna Mancini, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Viking Therapeutics Director Charles A Rowland Jr. exercised stock options and subsequently sold a portion of his common stock holdings.

Viking Therapeutics' President & CEO, Brian Lian, reported the vesting of performance-based restricted stock units and a subsequent sale of shares for tax obligations.

Viking Therapeutics' Chief Financial Officer, Greg Zante, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Viking Therapeutics' President and CEO, Brian Lian, reported the acquisition of 48,333 shares through RSU vesting and the subsequent sale of 26,889 shares for tax withholding purposes.

Viking Therapeutics' Chief Financial Officer, Zante Greg, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Viking Therapeutics' Chief Operating Officer, Marianna Mancini, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Matthew W. Foehr, a director at Viking Therapeutics, exercised stock options and disposed of 20,786 shares of common stock on April 11, 2025.

Director Sarah Kathryn Rouan amends her Form 4 filing to disclose a voluntary payment to Viking Therapeutics for profits realized from a short-swing transaction.

Director Sarah Kathryn Rouan purchased 1,240 shares of Viking Therapeutics (VKTX) at a price of $24.1474 per share on March 31, 2025.

Viking Therapeutics CEO Brian Lian acquired shares through vesting and sold some to cover tax obligations, according to a recent SEC filing.

Viking Therapeutics' Chief Operating Officer, Marianna Mancini, reported the acquisition and disposal of company stock and stock options, including sales to cover tax obligations.

Viking Therapeutics' Chief Financial Officer, Greg Zante, reported the acquisition and sale of company stock following the vesting of restricted stock units and performance-based awards.

Lawson Macartney, a director at Viking Therapeutics, acquired 18,800 stock options on January 2, 2025.

Viking Therapeutics director J Matthew Singleton acquired 18,800 stock options on January 2, 2025.

Viking Therapeutics director Charles A. Rowland Jr. acquired 18,800 stock options on January 2, 2025.